PTEN and prostate cancer: ITGA5 knockdown and the pharmacologic inhibition of BCL2-BCLXL had a synergistic effect with PI3K/AKT inhibitors in PTEN-mutant prostate cancer cells, such as LNCap and PC3, but not in PTEN-proficient DU145 cells [186].